印度的新型肺结核疫苗在试验中表现出希望, 并正在向商业用途发展, 以对抗全球重大健康威胁。 A new TB vaccine from India shows promise in trials and is advancing toward commercial use to combat a major global health threat.

印度Bhubaneswar理工学院和生命科学研究所在印度生物技术部和NRDC的支持下开发了一种新的结核病疫苗,即Adjuvant(DDA)HSP子单位疫苗,正在走向商业化。 A new tuberculosis vaccine, HSP Subunit Vaccine in Adjuvant (DDA), developed by Indian Institute of Technology Bhubaneswar and the Institute of Life Sciences with support from India’s Department of Biotechnology and NRDC, is moving toward commercialization. 新的疫苗旨在克服古老的卡介苗的局限性,特别是针对青少年和成年人肺部结核病的保护不足,新疫苗在临床前试验中表现出强烈的免疫反应。 Designed to overcome the limitations of the century-old BCG vaccine, especially its poor protection against pulmonary TB in adolescents and adults, the new vaccine has shown strong immune responses in pre-clinical trials. 与技术发明生命护理有限公司签订的四方协定有助于技术转让和临床发展。 A quadripartite agreement with TechInvention Lifecare Limited enables technology transfer and clinical development. 由于结核病在2024年造成123万人死亡,该疫苗是到2030年结束这一流行病的全球努力的一个重要步骤。 With TB causing 1.23 million deaths in 2024, the vaccine represents a significant step in global efforts to end the epidemic by 2030.